Skip to main content
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. — Investor Relations & Filings

Ticker · RLAY ISIN · US75943R1023 US Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2022-04-14 Proxy Solicitation & In…
Country US United States of America
Listing US RLAY

About Relay Therapeutics, Inc.

https://relaytx.com/

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming the drug discovery process. The company's approach is centered on understanding protein motion, utilizing its proprietary Dynamo® platform which integrates advanced computational and experimental methods. This platform enables the visualization of protein dynamics to design novel therapies for targets that have been historically considered intractable or 'undruggable'. Relay Therapeutics is advancing a pipeline of therapeutic candidates with an initial focus on precision oncology and genetic diseases.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a shareholder meeting. It includes details about the Annual Meeting of Stockholders, proposals to be voted on (such as election of directors, advisory votes on executive compensation, amendment to certificate of incorporation, and appointment of auditors), and voting instructions. This type of document is used to solicit shareholder votes and provide information necessary for voting decisions. It is not the actual annual report, earnings release, or other financial report, but rather proxy solicitation materials. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is not a brief announcement or a report publication notice, but the proxy statement itself or additional materials thereto.
2022-04-14 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-14 English
FORM 4 SUBMISSION
Director's Dealing
2022-04-05 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed on Schedule 14A with the SEC, related to the 2022 Annual Meeting of Stockholders of Relay Therapeutics, Inc. It includes detailed information about the meeting agenda, proposals to be voted on, board of directors nominations, executive compensation advisory votes, amendment to the certificate of incorporation, appointment of the independent auditor, and other governance matters. The document is not an announcement of voting results but the solicitation and information statement for the meeting. It is not a full Annual Report or financial report but a proxy solicitation document. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2022-04-01 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-31 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.